A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms MAIA
- Sponsors Janssen Research & Development; Janssen-Cilag
- 20 Dec 2024 Status changed from active, no longer recruiting to completed.
- 21 Oct 2024 Planned End Date changed from 1 Sep 2024 to 1 Oct 2024.
- 01 Jul 2024 Planned End Date changed from 27 Jun 2024 to 1 Sep 2024.